LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akcijų sąrašas・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

20.34 -13.52

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

19.55

Max

20.53

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-65M -180M
Pardavimai	-6.6M 160M
Pelno marža	-112.805
Darbuotojai	1,294
EBITDA	-65M -157M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+133.23% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-922M 2.3B
Ankstesnė atidarymo kaina	33.86
Ankstesnė uždarymo kaina	20.34

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

32.76 / 39.24 Palaikymas ir pasipriešinimas

Ultragenyx Pharmaceutical Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-13 16:32; UTC

Uždarbis

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

2026-02-14 22:02; UTC

Uždarbis

Looking for Dividends? Consider Europe. -- Barrons.com

2026-02-14 09:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-13 21:57; UTC

Uždarbis

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

2026-02-13 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-13 21:20; UTC

Uždarbis

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

2026-02-13 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

2026-02-13 20:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-13 20:45; UTC

Rinkos pokalbiai

Dollar Pares Down Early Losses -- Market Talk

2026-02-13 20:39; UTC

Rinkos pokalbiai

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

2026-02-13 20:28; UTC

Rinkos pokalbiai

Oil Settles Week Lower -- Market Talk

2026-02-13 19:51; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026-02-13 19:32; UTC

Rinkos pokalbiai

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026-02-13 19:32; UTC

Rinkos pokalbiai

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026-02-13 19:29; UTC

Uždarbis

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

2026-02-13 18:18; UTC

Įsigijimai, susijungimai, perėmimai

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

2026-02-13 17:52; UTC

Uždarbis

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

2026-02-13 17:16; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026-02-13 17:10; UTC

Įsigijimai, susijungimai, perėmimai

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

2026-02-13 16:59; UTC

Uždarbis

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

2026-02-13 16:39; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

2026-02-13 16:11; UTC

Uždarbis

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

2026-02-13 16:07; UTC

Rinkos pokalbiai

Hungarian Forint Could Rise Further -- Market Talk

2026-02-13 15:54; UTC

Uždarbis

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

2026-02-13 15:26; UTC

Rinkos pokalbiai

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

2026-02-13 15:01; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

2026-02-13 15:00; UTC

Uždarbis

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

2026-02-13 14:50; UTC

Rinkos pokalbiai

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

2026-02-13 14:44; UTC

Uždarbis

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

2026-02-13 14:22; UTC

Rinkos pokalbiai

Uždarbis

Global Energy Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ultragenyx Pharmaceutical Inc Prognozė

Kainos tikslas

By TipRanks

133.23% į viršų

12 mėnesių prognozė

Vidutinis 54.81 USD 133.23%

Aukščiausias 84 USD

Žemiausias 23 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ultragenyx Pharmaceutical Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

Pirkti

Laikyti

Parduoti

Remiantis 20 analitikų, pateikusių Ultragenyx Pharmaceutical Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

32.76 / 39.24Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.